摘要 |
<p>This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.</p> |
申请人 |
BAYER PHARMACEUTICALS CORPORATION;HENTEMANN, MARTIN;WOOD, JILL;SCOTT, WILLIAM;MICHELS, MARTIN;CAMPBELL, ANN-MARIE;BULLION, ANN-MARIE;ROWLEY, R., BRUCE;REDMAN, ANIKO |
发明人 |
HENTEMANN, MARTIN;WOOD, JILL;SCOTT, WILLIAM;MICHELS, MARTIN;CAMPBELL, ANN-MARIE;BULLION, ANN-MARIE;ROWLEY, R., BRUCE;REDMAN, ANIKO |